Can Truvada Cause Acid-Base Disturbance?
Yes, Truvada (emtricitabine/tenofovir disoproxil fumarate) can cause acid-base disturbances, specifically metabolic acidosis as part of Fanconi syndrome, a form of proximal renal tubular toxicity.
Mechanism and Clinical Presentation
Tenofovir disoproxil fumarate (TDF), the active component in Truvada, causes proximal renal tubule toxicity through concentration-dependent accumulation in proximal tubular cells 1. The resulting Fanconi syndrome manifests as metabolic acidosis along with hypophosphatemia, hypokalemia, proteinuria, glucosuria, and electrolyte wasting 1.
The FDA label explicitly warns that renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with tenofovir use 2. Treatment should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity 2.
Two Distinct Acid-Base Complications
1. Lactic Acidosis (Rare but Severe)
- Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with nucleoside analogs including tenofovir 2
- Risk factors include obesity, prolonged nucleoside exposure, and female sex 2
- Recent case reports document severe lactic acidosis with TDF, particularly when combined with cobicistat in underweight patients 3
- Even the newer tenofovir alafenamide (TAF) formulation has caused severe lactic acidosis in overdose situations 4
2. Distal Renal Tubular Acidosis (Very Rare)
- TDF can cause distal RTA presenting with normal anion gap metabolic acidosis, hypokalaemia, and urine pH >5.5 5
- This can manifest dramatically as hypokalaemic paralysis 5
- This complication is reversible with drug discontinuation 5
High-Risk Populations
Monitor especially closely in patients with:
- Low body weight or underweight status 3
- Concurrent use of ritonavir or cobicistat (increases tenofovir exposure by 32%) 1, 3
- Pre-existing renal dysfunction (eGFR <60 mL/min) 6
- Concurrent nephrotoxic agents (high-dose or multiple NSAIDs) 2
- Hepatitis B or C coinfection 1
Monitoring Requirements
The 2016 International Antiviral Society-USA guidelines mandate specific monitoring 6:
- Baseline: eGFR, urinalysis, urine glucose, urine protein
- At 3 months after initiation, then every 6 months: serum creatinine and creatinine clearance
- Every 6 months: testing for glycosuria and albuminuria/proteinuria
For PrEP use specifically, do not use Truvada in individuals with estimated creatinine clearance below 60 mL/min 2. If creatinine clearance decreases during PrEP use, evaluate potential causes and reassess risks versus benefits 2.
Management of Suspected Toxicity
Discontinue TDF/TAF immediately if renal function worsens, particularly with evidence of proximal tubular dysfunction (euglycemic glycosuria or urinary phosphate wasting) 6.
Clinical symptoms warranting immediate suspension include 2:
- Nausea, vomiting, unusual stomach discomfort, weakness (suggesting lactic acidosis)
- Persistent bone pain, pain in extremities, fractures, or muscular weakness (may indicate proximal renal tubulopathy)
Common Pitfall
The incidence of overt renal failure with tenofovir is relatively low (0.5-1.5% in cohort studies) 1, which can lead to complacency. However, subclinical tubular dysfunction may be present before creatinine rises. Always check urine glucose and phosphate, not just serum creatinine, as these are earlier markers of tubular toxicity.
For patients requiring continued antiretroviral therapy after TDF-related acid-base disturbance, switch to abacavir-based regimens (if HLA-B*5701 negative) or consider TAF only after complete resolution of tubulopathy, with close monitoring for recurrence 6.